FTC显示,药店中间商将非专利药物价格涨至高达1000 %,使数十亿患者付出了代价。 FTC reveals pharmacy middlemen inflate generic drug prices by up to 1,000%, costing patients billions.

美国联邦贸易委员会报告说, 药房福利管理公司 (PBM) 如快速处方, CVS Caremark 和 Optum RX 正在将通用处方药的价格提高至多1000%. The FTC reports that pharmacy benefit managers (PBMs) like Express Scripts, CVS Caremark, and Optum RX are inflating the prices of generic prescription drugs by as much as 1,000%. 这些中间人为80%的美国处方确定价格, 引导病人去自己的药店, 从2017年到2022年利润超过73亿美元。 These middlemen, who set prices for 80% of US prescriptions, steer patients to their own pharmacies, profiting over $7.3 billion from 2017 to 2022. 这种做法使癌症和艾滋病毒等疾病的药物成本上升。 This practice raises drug costs for conditions like cancer and HIV.